ArticleThe FEBS journal2019
Inhibition of Pseudomonas aeruginosa biofilm formation and expression of virulence genes by selective epimerization in the peptide Esculentin-1a(1-21)NH
Article in The FEBS journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- In vitro antibiofilm activity of dermcidin derived peptides against Pseudomonas aeruginosa and Staphylococcus aureus pathogens.Molecular biology reports · 2026Article
- Antimicrobial Peptides for Skin Wound Healing.Biomolecules · 2025Review
- The Esc(1-21)-1c Antimicrobial Peptide Inhibits a Specific Transcriptional Activator of the MexAB-OprM Efflux Pump inInternational journal of molecular sciences · 2025Article
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Anti-Biofilm Agents to OvercomePharmaceuticals (Basel, Switzerland) · 2025Review
- Biofilm Production in Intensive Care Units: Challenges and Implications.Pathogens (Basel, Switzerland) · 2024Review
- Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.Physiological reviews · 2024Review
- An esculentin-1 homolog from a dark-spotted frog (Pelophylax nigromaculatus) possesses antibacterial and immunoregulatory properties.BMC veterinary research · 2024Article
- An Overview of Frog Skin-Derived Esc Peptides: Promising Multifunctional Weapons againstInternational journal of molecular sciences · 2024Review
- Fighting Microbial Infections fromAntibiotics (Basel, Switzerland) · 2024Article
- Biofilm formation: mechanistic insights and therapeutic targets.Molecular biomedicine · 2023Review
- Antimicrobial Peptides Originating from Expression Libraries ofMicroorganisms · 2023Article
- FightingInternational journal of molecular sciences · 2023Article
- Improving the Management and Treatment of Diabetic Foot Infection: Challenges and Research Opportunities.International journal of molecular sciences · 2023Review
- The antimicrobial peptide Esc(1-21)-1c increases susceptibility ofFrontiers in chemistry · 2023Article
- GC-MS Analysis and Microbiological Evaluation of Caraway Essential Oil as a Virulence Attenuating Agent againstMolecules (Basel, Switzerland) · 2022Article
- HybridACS omega · 2022Article
- Knocking down Pseudomonas aeruginosa virulence by oral hypoglycemic metformin nano emulsion.World journal of microbiology & biotechnology · 2022Article
- Derivatives of Esculentin-1 Peptides as Promising Candidates for Fighting Infections fromAntibiotics (Basel, Switzerland) · 2022Article
- KDEON WK-11: A short antipseudomonal peptide with promising potential.Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
Pseudomonas aeruginosa is a pathogenic bacterium known to cause serious human infections, especially in immune-compromised patients. This is due to its unique ability to transform from a drug-tolerant planktonic to a more dangerous and treatment-resistant sessile life form, called biofilm. Recently, two derivatives of the frog skin antimicrobial peptide esculentin-1a, i.e. Esc(1-21) and its D-amino acids containing diastereomer Esc(1-21)-1c, were characterized for their powerful anti-Pseudomonal activity against both forms. Prevention of biofilm formation already in its early stages could be even more advantageous for counteracting infections induced by this bacterium. In this work, we studied how the diastereomer Esc(1-21)-1c can inhibit Pseudomonas biofilm formation in comparison to the parent peptide and two clinically-used conventional antibiotics, i.e. colistin and aztreonam, when applied at dosages below the minimal growth inhibitory concentration. Biofilm prevention was correlated to the peptides' ability to inhibit Pseudomonas motility and to reduce the production of virulent metabolites, for example, pyoverdine and rhamnolipids. Furthermore, the molecular mechanism underlying these activities was evaluated by studying the peptides' effect on the expression of key genes involved in the virulence and motility of bacteria, as well as by monitoring the peptides' binding to the bacterial signaling nucleotide ppGpp. Our results demonstrate that the presence of only two D-amino acids in Esc(1-21)-1c is sufficient to downregulate ppGpp-mediated expression of biofilm-associated genes, presumably as a result of higher peptide stability and therefore prolonged interaction with the nucleotide. Overall, these studies should assist efficient design and optimization of new anti-infective agents with multiple pharmacologically beneficial properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.